title: Protease inhibitor-induced diabetic complications : incidence, management and prevention.
abstract: Protease inhibitors (PIs) have become a crucial element in the treatment of patients infected with HIV. However, the widespread use of PI therapy has also been associated with a number of metabolic adverse effects, including fat redistribution and hyperglycaemia. The objective of this review is a discussion of the incidence, pathophysiology, management and prevention of PI-associated hyperglycaemia. Initial case reports have been followed by large cross-sectional and cohort studies, which demonstrate that the incidence of PI-induced impaired glucose tolerance, as well as frank diabetes mellitus, is significant and demands attention. Investigations into the pathophysiology behind PI-associated hyperglycaemia have identified an underlying problem of insulin resistance that is presumably caused by both direct PI-induced mechanisms and lipotoxicity. Given this, clinical trials have explored the use of various classes of oral hypoglycaemic agents in the management of PI-induced diabetic complications, and the use of insulin therapy must be considered as well. Newer PI agents are also under development, with the hope of reducing metabolic adverse effects. In the meantime, prevention, in the form of dietary modification, regular physical activity and periodic screening for impaired glucose tolerance, must receive heightened attention in the care plan of patients receiving long-term PI therapy.
authors.affiliation: Division of Endocrinology, Metabolism, and Nutrition, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA. lien0002@mc.duke.edu
authors.forename: Lillian F
authors.initials: LF
authors.lastname: Lien
authors.forename: Mark N
authors.initials: MN
authors.lastname: Feinglos
mesh_terms: D048909:Diabetes Complications / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control*; D004358:Drug Therapy; D006801:Humans; D006943:Hyperglycemia / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control; D011480:Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D011480:Protease Inhibitors
references.citation: Clin Infect Dis. 2002 Jan 15;34(2):248-59
references.pmid: 11740715
references.citation: J Clin Endocrinol Metab. 2000 Oct;85(10):3544-50
references.pmid: 11061499
references.citation: Clin Infect Dis. 2002 Aug 15;35(4):475-81
references.pmid: 12145733
references.citation: J Acquir Immune Defic Syndr. 2002 Nov 1;31(3):257-75
references.pmid: 12439201
references.citation: Clin Infect Dis. 2001 Sep 1;33(5):710-7
references.pmid: 11486294
references.citation: Lancet. 1995 Jul 8;346(8967):120-1
references.pmid: 7603193
references.citation: AIDS. 1998 May 7;12(7):F51-8
references.pmid: 9619798
references.citation: J Acquir Immune Defic Syndr. 2000 Jan 1;23(1):35-43
references.pmid: 10708054
references.citation: AIDS Patient Care STDS. 2002 Dec;16(12):585-97
references.pmid: 12542932
references.citation: AIDS. 2002 Jul 5;16(10):1341-9
references.pmid: 12131210
references.citation: Diabet Med. 1998 Jul;15(7):539-53
references.pmid: 9686693
references.citation: JAMA. 2001 Oct 24-31;286(16):1945-8
references.pmid: 11667913
references.citation: AIDS. 1999 Jul 9;13(10):F63-70
references.pmid: 10416516
references.citation: Ann Pharmacother. 2004 Oct;38(10):1664-74
references.pmid: 15353575
references.citation: Diabetes. 2002 Nov;51(11):3163-9
references.pmid: 12401706
references.citation: Diabetes. 2002 Apr;51(4):937-42
references.pmid: 11916910
references.citation: AIDS. 1998 Jul 30;12(11):1399-400
references.pmid: 9708427
references.citation: Clin Infect Dis. 2002 May 15;34(10):1396-405
references.pmid: 11981737
references.citation: AIDS. 2000 May 5;14(7):903-5
references.pmid: 10839604
references.citation: J Biol Chem. 2000 Jul 7;275(27):20251-4
references.pmid: 10806189
references.citation: J Acquir Immune Defic Syndr. 1999 Jul 1;21(3):209-16
references.pmid: 10421244
references.citation: N Engl J Med. 2003 Sep 11;349(11):1036-46
references.pmid: 12968087
references.citation: AIDS. 1999 May 7;13(7):805-10
references.pmid: 10357379
references.citation: AIDS. 2002 Mar 29;16(5):F1-8
references.pmid: 11964551
references.citation: J Clin Endocrinol Metab. 2000 Jan;85(1):35-41
references.pmid: 10634360
references.citation: Clin Endocrinol (Oxf). 2000 Feb;52(2):241-3
references.pmid: 10671953
references.citation: Ann Pharmacother. 2000 May;34(5):580-4
references.pmid: 10852083
references.citation: J Infect Dis. 2001 Nov 1;184(9):1197-201
references.pmid: 11598845
references.citation: Control Clin Trials. 2001 Apr;22(2):142-59
references.pmid: 11306153
references.citation: AIDS. 1999 Oct 1;13(14):1987-9
references.pmid: 10513665
references.citation: Arch Intern Med. 2002 Dec 9-23;162(22):2621-8
references.pmid: 12456235
references.citation: JAMA. 2000 Jul 26;284(4):472-7
references.pmid: 10904511
references.citation: J Intern Med. 2002 Dec;252(6):570-4
references.pmid: 12472919
references.citation: AIDS Alert. 2003 Jan;18(1):6
references.pmid: 12541993
references.citation: Clin Infect Dis. 2000 Dec;31(6):1467-75
references.pmid: 11096014
references.citation: J Clin Endocrinol Metab. 2003 May;88(5):1961-76
references.pmid: 12727939
references.citation: Arch Med Res. 2000 Jan-Feb;31(1):81-4
references.pmid: 10767485
references.citation: J Clin Endocrinol Metab. 1999 Jun;84(6):1932-7
references.pmid: 10372689
references.citation: Diabetes Care. 1997 Jul;20(7):1183-97
references.pmid: 9203460
references.citation: Am J Physiol Endocrinol Metab. 2003 Feb;284(2):E274-80
references.pmid: 12388139
references.citation: Lancet. 1999 Jun 19;353(9170):2093-9
references.pmid: 10382692
references.citation: Antivir Ther. 2003 Jun;8(3):199-207
references.pmid: 12924536
references.citation: AIDS. 2003 May 23;17(8):1179-93
references.pmid: 12819520
references.citation: Clin Infect Dis. 2002 Mar 1;34(5):716-7
references.pmid: 11823959
references.citation: AIDS. 2001 Apr 13;15(6):717-23
references.pmid: 11371686
references.citation: Ann Intern Med. 1997 Nov 15;127(10):947
references.pmid: 9382374
references.citation: Arch Intern Med. 2000 Jul 10;160(13):2050-6
references.pmid: 10888979
references.citation: Ann Pharmacother. 2001 Jul-Aug;35(7-8):877-80
references.pmid: 11485138
references.citation: Ann Intern Med. 2004 May 18;140(10):786-94
references.pmid: 15148065
references.citation: J Acquir Immune Defic Syndr. 2001 Dec 1;28(4):399-401
references.pmid: 11707680
references.citation: AIDS. 1999 May 28;13(8):1000-2
references.pmid: 10371188
references.citation: Lancet. 2004 Feb 7;363(9407):429-38
references.pmid: 14962523
references.citation: Lancet. 1997 Sep 6;350(9079):713-4
references.pmid: 9291911
references.citation: Diabetes. 2003 Apr;52(4):918-25
references.pmid: 12663461
references.citation: Ann Intern Med. 1997 Nov 15;127(10):948
references.pmid: 9382376
references.citation: Ann Intern Med. 1999 Aug 17;131(4):281-303
references.pmid: 10454950
references.citation: J Clin Endocrinol Metab. 2001 Feb;86(2):939-43
references.pmid: 11158071
references.citation: CMAJ. 1999 Jul 27;161(2):161-4
references.pmid: 10439826
references.citation: Metabolism. 1997 Dec;46(12 Suppl 1):35-9
references.pmid: 9439557
references.citation: AIDS. 2003 May 2;17(7):987-99
references.pmid: 12700448
references.citation: Res Exp Med (Berl). 2000 Apr;199(5):253-62
references.pmid: 10815754
references.citation: Diabetologia. 1985 Jul;28(7):412-9
references.pmid: 3899825
references.citation: J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):163-70
references.pmid: 12394794